amonafide has been researched along with cytarabine in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Tallman, M | 1 |
Allen, SL; Bennett, JM; Budman, DR; Capizzi, RL; Kolitz, JE; Lundberg, AS | 1 |
Feldman, EJ | 1 |
Allen, SL; Damon, L; Egyed, M; Erba, HP; Horst, HA; Jang, JH; Lundberg, AS; Masszi, T; Mazzola, E; Neuberg, D; Pigneux, A; Powell, B; Rizzieri, D; Sekeres, MA; Selleslag, D; Solomon, SR; Stone, RM; Stuart, RK; Tallman, MS; Venugopal, P; Warzocha, K; Wetzler, M | 1 |
2 trial(s) available for amonafide and cytarabine
Article | Year |
---|---|
Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthalimides; Organophosphonates; Remission Induction; Risk Factors; Treatment Outcome; Young Adult | 2010 |
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthalimides; Organophosphonates; Prospective Studies; Remission Induction; Time Factors; Treatment Outcome; Young Adult | 2015 |
2 other study(ies) available for amonafide and cytarabine
Article | Year |
---|---|
Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.
Topics: Adenine; Adenine Nucleotides; Aminoglycosides; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Carbazoles; Clofarabine; Cytarabine; Dasatinib; Daunorubicin; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Naphthalimides; Organophosphonates; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sesquiterpenes; Staurosporine; Stem Cell Transplantation; Thiazoles; Tretinoin | 2008 |
Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants?
Topics: Adenine; Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Cytarabine; Cytogenetics; Female; Germany; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Naphthalimides; Naphthyridines; Organophosphonates; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Thiazoles | 2011 |